CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

About this update from Jp Morgan Chase & Co.

[{"type":"image","alt":"CorMedix, Inc.","displaySize":"","headline":null,"caption":"CorMedix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":202,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/51f441ac293f999ee517fc590cd80730"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c5OvX2_NmCuvbl9BhVk81Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/51f441ac293f999ee517fc590cd80730","width":202,"height":45}},"lazy":false},{"type":"text","content":"BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.","length":487,"tagName":"p"},{"type":"text","content":"44th Annual J.P. Morgan Healthcare Conference","length":45,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:10%;width:10%;min-width:10%;","val":[{"type":"text","content":"Date:","length":5,"tagName":"p","attribs":{}}]},{"style":"max-width:90%;width:90%;min-width:90%;","val":[{"type":"text","content":"Monday, January 12, 2026","length":24,"tagName":"p","attribs":{}}]}]},{"val":[{"val":[{"type":"text","content":"Time:","length":5,"tagName":"p"}]},{"val":[{"type":"text","content":"4:30pm PST","length":10,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Format:","length":7,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation","length":12,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Webcast:","length":8,"tagName":"p"}]},{"style":"text-align:justify;vertical-align:middle;","val":[{"type":"text","content":"Link","length":4,"tagName":"p","attribs":{}}]}]}],"length":75},{"type":"text","content":"About CorMedix","length":14,"tagName":"p"},{"type":"text","content":"CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for th...

More updates from Jp Morgan Chase & Co.